Methods and Compositions for Dengue Virus Vaccines
US-2016257719-A1 · Sep 8, 2016 · US
Methods and compositions for dengue virus serotype 4 epitopes
US11241491B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11241491-B2 |
| Application number | US-201816615350-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 23, 2018 |
| Priority date | May 23, 2017 |
| Publication date | Feb 8, 2022 |
| Grant date | Feb 8, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce a dengue virus E glycoprotein epitope from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.
First claim
Opening claim text (preview).
What is claimed is: 1. A chimeric dengue virus E glycoprotein comprising an amino acid sequence selected from the group consisting of: (SEQ ID NO: 8) MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEA KEVALLRTYCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFVCKHSMVDRG WGNGCGLFGKGGIVTCAMFTCKKKITGNLVQPENLEYTIVVTPHSGEEHA VGNDTGKHGKEIKVTPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLK MKKKTWLVHKQWFLDLPLPWTAGADTQGSNWIQKETLVTFKNPHAKKQDV VVLGSQEGAMHTALTGATEVDSGDGNHMFAGHLKCRLRMDKLQLKGMSYS MCTGKFKVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGR LITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVDPGQLKLNWFKK; (SEQ ID NO: 9) MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEA KEVALLRTYCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFVCKHSMVDRG WGNGCGLFGKGGIVTCAKFSCSGKITGNLVQPENLEYTIVVTPHSGEEHA VGNDTGKHGKEIKVTPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLK MKKKTWLVHKQWFLDLPLPWTAGADTSEVHWNYKETLVTFKNPHAKKQDV VVLGSQEGAMHTALTGATEVDSGDGNHMFAGHLKCRLRMDKLQLKGMSYS MCTGKFKVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGR LITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVDPGQLKLNWFKK ; (SEQ ID NO: 10) MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELTKTTA KEVALLRTYCIEASISNITTASRCPTQGEPYLKEEQDQQYICKHSMVDRG WGNGCGLFGKGGIVTCAKFSCSGKITGNLVQPENLEYTIVVTPHSGEEHA VGNDTGKHGKEIKVTPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLK MKKKTWLVHKQWFLDLPLPWTAGADTSEVHWNYKETLVTFKNPHAKRQDV TVLGSQEGAMHTALTGATEVDSGDGNHMFAGHLKCRLRMDKLQLKGMSYS MCTGKFKVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGR LITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVDPGQLKLNWFKK ; (SEQ ID NO: 22) MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELTKTTA KEVALLRTYCIEAKLTNTTTESRCPTQGEPSLNEEQDKRFVCKHSMVDRG WGNGCGLFGKGGIVTCAKFSCSGKITGNLVQIENLEYTIVVTPHSGEEHA VGNDTGKHGKEIKVTPOSSITEAELTGYGTVTMECSPRSGIDFNEMVLLK MKKKTWLVHKQWFLDLPLPWTAGADTSEVHWNDKETLVTFKNPHAKKQDV VVLGSQEGAMHTALTGATEVDSGDGNHMFAGHLKCRLRMDKLQLKGMSYS MCTGKFKVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGR LITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVDPGQLKLNWFKK . (SEQ ID NO: 24) MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELTKTTA KEVALLRTYCIEAKISNITTESRCPTQGEPYLKEEQDQQYICKHSMVDRG WGNGCGLFGKGGIVTCAKFSCSGKITGNLVQPENLEYTIVVTPHSGEEHA VGNDTGKHGKEIKVTPQSSITEAELTGYGTVTMECSPRTGLDFNEMVLLK MKKKTWLVHKQWFLDLPLPWTAGADTSEVHWNYKETLVTFKNPHAKKQDV TVLGSQEGAMHTALTGATEVDSGDGNHMFAGHLKCRLRMDKLQLKGMSYS MCTGKFKVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGR LITVNPIVTEKDSPVNIEAEPPFGDSYIIIGVDPGQLKLNWFKK ; (SEQ ID NO: 25) MRCIGISNRDFVEGVSGGSWVDIVLEHGSCVTTMAKNKPTLDFELIKTEA KEVALLRTYCIEASISNITTATRCPTQGEPYLKEEQDQQYICRRDVVDRG WGNGCGLFGKGGVVTCAKFSCSGKITGNLVQIENLEYTIVVTPHSGEEHA VGNDTGKHGKEIKVTPQSSITEAELTGYGTVTMECSPRTGLDFNEMILMK MKKKTWLVHKQWFLDLPLPWTAGADTSEVHWNYKERMVTFKVPHAKRQDV TVLGSQEGAMHSALAGATEVDSGDGNHMFTGHLKCRLRMDKLQLKGMSYS MCTGKFKVVKEIAETQHGTIVIRVQYEGDGSPCKIPFEIMDLEKRHVLGR
Assignees
Inventors
Classifications
Togaviridae (F); Matonaviridae (F); Flaviviridae (F) · CPC title
Multivalent vaccine · CPC title
- A61P31/12Primary
Antivirals · CPC title
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11241491B2 cover?
- The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce a dengue virus E glycoprotein epitope from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.
- Who is the assignee on this patent?
- Univ North Carolina Chapel Hill
- What technology area does this patent fall under?
- Primary CPC classification A61P31/12. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).